Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immune Thrombocytopenic Purpura Autoimmune Diseases Blood Coagulation Disorders Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombotic Microangiopathies

Sex eligibility

All sexes

Study type

Observational

Primary location

Jiangsu Institute of Hematology

Suzhou, Jiangsu, 215006, China

About this study

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnoses of idiopathic thrombocytopenic purpura
Hormone and immune suppression, splenectomy is invalid

Exclusion criteria

patients had a bad tolerance to rapamycin
platelet counts < 10*10E9/L during the treatment of rapamycin

Treatment and study plan

Rapamycin

Drug

4mg oral administration on the first day, 2 mg/d oral administration for 3 months

Other names: sirolimus

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Suzhou Medical College

Other

Registry information

Acronym: ITP

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2012
First posted: Aug 24, 2012
Registry last updated: Aug 24, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed